Breaking News
Home / Oncology (page 152)

Oncology

Catamaran Report Finds Drug Inflation and Increased Specialty Utilization Drives Increase in Drug Trend

Increased specialty utilization and drug inflation were the driving factors for overall drug trend more than doubling in 2014, according to a new report. Pharmacy Benefit Manager (PBM) Catamaran Corp. today released its annual Informed Trends report for 2014. Overall commercial drug trend was 5.7 percent in 2014, more than …

Read More »

Merck Teams Up with Syndax to Test Cancer Combination Regimen

Merck has teamed up with privately-held Syndax Pharmaceuticals to test combining Syndax’s investigational epigenetic therapy, entinostat, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in cancer patients. The companies announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of this novel combination regimen in patients …

Read More »

Merck Serono and Intrexon Strike CAR-T Therapy Collaboration

Merck Serono is partnering with Intrexon Corporation to develop Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The companies announced today that they have entered an exclusive strategic collaboration and license agreement for CAR-T cancer drugs, advancing Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s …

Read More »

Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech

Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …

Read More »

RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …

Read More »

Drug Companies Join Initiative to Decode 100,000 Human Genomes

A group of leading drugmakers have joined Genomics England in a new collaboration as part of the 100,000 Genomes Project, aimed at accelerating the development of new drugs and diagnostics. Ten biopharma companies have joined together to create the Genomics Expert Network for Enterprises (GENE) Consortium, to oversee a year-long …

Read More »

FDA Grants Orphan Drug Designation to Aduro’s Mesothelioma Candidate

Today, Aduro Biotech Inc. announced that US health regulators have granted Orphan Drug designation to its novel, immuno-oncology candidate. The company said that the Office of Orphan Product Development of the US Food and Drug Administration (FDA) granted orphan drug designation to CRS-207, Aduro’s novel immuno-oncology product candidate in development …

Read More »